These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27262619)

  • 21. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Venkatesh R; Dave PA; Singh S; Gurav P; Gujral G
    Am J Ophthalmol; 2016 Oct; 170():246-247. PubMed ID: 27594519
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2017 Jan; 173():145-146. PubMed ID: 27842696
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ASSESSMENT OF VASCULAR EFFECTS OCCURRING AFTER AFLIBERCEPT INTRAVITREAL INJECTIONS IN TREATMENT-NAIVE PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION.
    Mastropasqua L; Toto L; Borrelli E; Carpineto P; Di Antonio L; Mastropasqua R
    Retina; 2017 Feb; 37(2):247-256. PubMed ID: 27628926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
    Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
    Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H; Weber ML; Shah CP; Heier JS
    Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
    Nomura Y; Yanagi Y
    Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat-and-Extend Regimen.
    Türksever C; Prünte C; Hatz K
    Ophthalmologica; 2017; 238(3):172-178. PubMed ID: 28772268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial.
    Hatz K; Prünte C
    Retina; 2017 Jun; 37(6):1185-1192. PubMed ID: 27652915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.
    Nestel AR
    Eye (Lond); 2018 Feb; 32(2):477-479. PubMed ID: 29026187
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to: 'Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.
    Almuhtaseb H; Lotery A
    Eye (Lond); 2018 Feb; 32(2):479-481. PubMed ID: 29052610
    [No Abstract]   [Full Text] [Related]  

  • 38. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
    BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal pigment epithelial tear after intravitreal aflibercept for neovascular age-related macular degeneration.
    Sato T; Ooto S; Suzuki M; Spaide RF
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):87-90. PubMed ID: 25559517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.